atent Application of

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

O'MAHONY ET AL

Atty. Ref.: 3659-40

Serial No.

10/073,855

Group: 3762

Filed: February 14, 2002

Examiner: Leslie R. DEAK

For: METHOD AND APPARATUS FOR AN EXTRACORPOREAL TREATMENT DEVICE TO CONTROL BLOOD WITHDRAWAL

AND INFUSION

April 22, 2004

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

INFORMATION DISCLOSURE STATEMENT

	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action]	N/C			
	2.	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance]	N/C			
\boxtimes	3.	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance]	\$180.00			
	4.	Statement & Fee Payment Pursuant to 37 CFR 1.97(d) [before Issue Fee payment]	\$180.00			
⊠ Γhis μ	5. paper i	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document is enclosed herewith.				
	6.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st 0	Office Action]			

용

O'MAHONY ET AL Serial No. 10/073,855

\boxtimes						
	7.	37 C	FR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and			
		a)	The Statement required by 37 CFR §§1.97(c)(1) and (e) made in item 9 below; or			
		b)	The fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 10 below.			
	8.	37 CFR §1.97(d): [before issue fee payment]; and				
		a)	This is a request for consideration of the subject Information Disclosure Statement. The fee required by 37 CFR §1.17(p) is authorized in item 10 below; and			
		b)	The Statement required by 37 CFR §§1.97(d)(1) and (e) is stated in item 9 below.			
	9.	State	ement under 37 CFR 1.97(e)			
		a) Each item of information contained in this Information Disclosure Statement we cited for the first time in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Each of the filing of th				
			this Information Disclosure Statement; or			
\boxtimes		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
	10.	Disc	se charge all applicable fees associated with the submission of this Information closure Statement and any other fees applicable to this application to Deposit ount No. 14-1140. An original and one (1) copy of this document are enclosed.			
			Respectfully submitted,			
			NIXON & VANDERHYE P.C.			
			By: Setfry H. Nelson Reg. No. 30,481			
HN:gl		llebe R	oad, 8th Floor			

JF

Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

INFORMATION	DISCLOSURE
CITAT	TION

ATTY. DOCKET NO.

SERIAL NO.

3659-40

10/073,855

APPLICANT

O'MAHONY ET AL

(Use several sheets if necessary)

FILING DATE

TC/A.U.

February 14, 2002

3762



U.S.	PAT	ENT	DOC	UMENTS
------	-----	-----	-----	--------

			NO. I ATENT DOCUMENTO			
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCI ASS	FILING DATE IF APPROPRIATE
INTUAL	4,784,768	11/15/1988	Mathieu	ULAGO	JOBOLAGO	II ALTHOLINATE
	US 2001/0016699 A1	08/23/2001	Burbank et al.			
	US 2001/0021817 A1	09/13/2001	Brugger et al.			
	US 2001/0037079 A1	11/01/2001	Burbank et al.			
	US 2001/0041892 A1	11/15/2001	Burbank et al.			
	US 2002/0103453 A1	08/01/2002	Burbank et al.			
	US 2002/0147423 A1	10/10/2002	Burbank et al.			
	US 2003/0009123 A1	01/09/2003	Brugger et al.		Ī	
	US 2003/0097087 A1	05/22/2003	Gura			
	5,366,630	11/1994	Chevallet			-
	5,730,712	03/1998	Falkvall et al			
				<u> </u>		

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	LATION NO
0 274 178	7/13/88	Europe (Fisher)				
1 583 023	1/21/81	Great Britain (Lavender)				
0 990 444 A2	4/5/00	Europe (Davidner)				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

 OTTIEN DOCUMENTS (including Additor, Thie, Date, 1 entirent pages, etc.)					
International Search Report dated September 11, 2002.					
Jonathan D. Sackner-Bernstein, MD et al., "How Should Diuretic-Refractory, Volume-Overloaded Heart Failure Patients					
 Be Managed?" The Journal of Invasive Cardiology, Vol. 15, No. 10 (October 2003), pp. 585-590.					
Brian E. Jaski, MD et al., "Peripherally Inserted Veno-Venous Ultrafiltration for Rapid Treatment of Volume Overloaded					
Patients", Journal of Cardiac Failure, Vol. 9, No. 3, (June 2003), pp. 227-231.					

		1
Examiner	Date Considered	1

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.